EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Linking volatile metabolites from bacterial pathogens to exhaled breath condensate of people with cystic fibrosis

P Hansani Karunarathne, Christopher Bridges, Lacy Remisoski, Madisen Crane, Claudia Soria Casanova, Samantha N Kinne, Alicia L Castillo Bahena, Marissa Gil, Lienwil Padillo, Gabriel Querido, Jenna Mielke, Marc McClelland und 2 weitere

Microbiology · 2025

DOI: 10.1099/mic.0.001536 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology, 2025. Verfasst von P Hansani Karunarathne und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Volatile Organic Compounds, Bacteria. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, National Institute of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obtaining sputum samples from people with cystic fibrosis (pwCF) for microbiology has become challenging due to the positive clinical effects of the cystic fibrosis transmembrane conductance regulator modulator therapy, elexacaftor-tezacaftor-ivacaftor (ETI). Although ETI improves lung function and reduces sputum production, recent data shows that bacterial pathogens persist, making continued monitoring of infection important. As an alternative to sputum sampling, this study developed a non-invasive technique called ‘Cough Breath’ (CB) to identify volatile organic compounds (VOCs) in exhaled breath condensate (EBC) and link them to cystic fibrosis (CF) bacterial pathogens using purge and trap GC-MS. The CB culturing approach was able to isolate pathogens from expectorated particulates simultaneously with EBC collection; however, culturing positivity was low, with 6% of samples collected ( n =47) positive for either Pseudomonas aeruginosa or Staphylococcus aureus . From EBC, we identified VOCs matching those uniquely produced by P. aeruginosa (7), S. aureus (12), Achromobacter xylosoxidans (8) and Granulicatella adiacens (2); however, the overall detection rate was also low. Expanding to VOCs produced across multiple pathogens identified 30 frequently detected in the EBC of pwCF, including 2,3-pentanedione, propyl pyruvate, oxalic acid diallyl ester, methyl isobutyl ketone, methyl nitrate, 2-propenal, acetonitrile, acetoin and 2,3-butanedione. Comparing isolate volatilomes and EBC samples from the same pwCF enhanced detection rates with key VOCs, such as 2,3-pentanedione (86%) and propyl pyruvate (83%), in P. aeruginosa isolates. Further investigation showed that VOC production differed across strains and at different growth phases, creating variability that may explain the overall low EBC detection rate. Although this study successfully cultured CF pathogens from cough particulates and matched their unique VOCs in EBC samples, our results indicate that microbial volatiles more generally indicative of infection, such as 2,3-pentanedione, may have the most utility in aiding diagnostics in pwCF on ETI who have reduced sputum production in the clinic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisVolatile Organic CompoundsBacteriaHumansBreath TestsMaleAdultFemaleSputumGas Chromatography-Mass SpectrometryPseudomonas aeruginosaYoung Adult

Stichwörter der Autor:innen

cough breathcystic fibrosisexhaled breath condensatepathogensvolatile organic compounds

Substanzen

Volatile Organic Compounds

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI, USA.
  • Corewell Health, Grand Rapids, MI, USA.
  • Department of Medicine, University of California San Diego, La Jolla, CA, USA.
  • Microbiology, Genetics and Immunology, Michigan State University, East Lansing, MI, USA.

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases, National Institute of Health

Zitieren

APA

Karunarathne, P. H., Bridges, C., Remisoski, L., Crane, M., Casanova, C. S., Kinne, S. N., Castillo Bahena, A. L., Gil, M., Padillo, L., Querido, G., Mielke, J., McClelland, M., Conrad, D., & Quinn, R. A. (2025). Linking volatile metabolites from bacterial pathogens to exhaled breath condensate of people with cystic fibrosis. Microbiology. https://doi.org/10.1099/mic.0.001536

Vancouver

Karunarathne PH, Bridges C, Remisoski L, Crane M, Casanova CS, Kinne SN, et al. Linking volatile metabolites from bacterial pathogens to exhaled breath condensate of people with cystic fibrosis. Microbiology. 2025. doi:10.1099/mic.0.001536

BibTeX
@article{Karunarathne2025,
  author = {Karunarathne, P Hansani and Bridges, Christopher and Remisoski, Lacy and Crane, Madisen and Casanova, Claudia Soria and Kinne, Samantha N and Castillo Bahena, Alicia L and Gil, Marissa and Padillo, Lienwil and Querido, Gabriel and Mielke, Jenna and McClelland, Marc and Conrad, Doug and Quinn, Robert A},
  title = {Linking volatile metabolites from bacterial pathogens to exhaled breath condensate of people with cystic fibrosis},
  journal = {Microbiology},
  year = {2025},
  doi = {10.1099/mic.0.001536}
}
Kostenlos starten →